COPY OF PAPERS ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S)

Robert Amess et al

SERIAL NO.

09/936,408

FILED

January 8, 2002

FOR

PROTEINS FOR DIAGNOSIS AND TREATMENT OF

BREAST CANCER

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on February 6, 2002

David A. Jackson, Reg. #26,742

(Name of Registered Representative)

RECEIVED
TECHCENTER 1800/2000

REQUEST FOR CORRECTED FILING RECEIPT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Attention:

Office of Initial Patent Examination's

Customer Service Center

Dear Sir:

Applicants hereby request that a corrected Formal Filing Receipt (PTO-103X) be issued to correct the spelling of the fourth listed co-inventor in the above-identified Application.

Please correct the spelling of the inventor "Robert Reid Townsen" to read

--Robert Reid Townsend--

as it appears on the Declaration and Power of Attorney, copy of which is enclosed.

A copy of the filing receipt with the requested correction marked in red is also enclosed.

As these errors were on the part of the Patent Office, no fees are believed to be due.

Applicants accordingly request that the records of the U.S. Patent and Trademark

Office be corrected to reflect the correct spelling of the title.

Respectfully submitted,

David X Jackson

Attorney for Applicant Registration No. 26,742

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, NJ 07601 (201) 487-5800 Enclosures





DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

COPY OF PAPERS PROTEINS FOR DIAGNOSIS AND TREATMENT OF BREAST CANCER ORIGINALLY FILED

the Specification of which

[] is attached hereto

was filed on March 13, 2000

as International Application No. PCT/GB00/00908, and filed at the

U.S. Patent and Trademark Office on September 12, 2001.

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN FILED APPLICATION(S)

APPLICATION COUNTRY **NUMBER**

9905817.4

(MONTH/DAY/YYYY)

PRIORIT

Great Britain March 12, 1999

YES

MAR I 3 2000 DO I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER(S)

FILING DATE (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Parent Parent Filing Parent Patent

Application No. Number (MM/DD/YYYY) Number (if applicable)

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from Oxford GlycoSciences (UK) Ltd as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint as my attorneys or agents the registered persons identified under

Customer No. 23565

for the law firm of Klauber & Jackson, said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to Customer No. 23565.

DAVID A. JACKSON, ESQ. KLAUBER & JACKSON 411 HACKENSACK AVENUE HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST OR SOLE INVENTOR: Robert Amess

COUNTRY OF CITIZENSHIP:	United Kingdom
FULL RESIDENCE ADDRESS:	Cumnor, Oxon, United Kingdom
FULL POST OFFICE ADDRESS:	The Forum 86 Milton Park Abingdon, Oxon OX14 4RY United Kingdom
SIGNATURE OF INVENTOR	Amen
DATE 31/10/01	
FULL NAME OF SECOND JOINT INVEN	NTOR: Michael John O'Hare
COUNTRY OF CITIZENSHIP:	United Kingdom
FULL RESIDENCE ADDRESS:	London, United Kingdom
FULL POST OFFICE ADDRESS:	Ludwig Institute for Cancer Research 91 Riding House Street London, W1P 8BT United Kingdom
	n,
SIGNATURE OF INVENTOR	1.81
DATE 264 SCT SECT	

FULL NAME OF THIRD JOINT INVENTOR: Rajesh Bhikhu Parekh	
COUNTRY OF CITIZENSHIP:	United Kingdom
FULL RESIDENCE ADDRESS:	Nr. Wendlebury, Oxon, United Kingdom
FULL POST OFFICE ADDRESS:	The Forum 86 Milton Park Abingdon, Oxon OX14 4RY United Kingdom
SIGNATURE OF INVENTOR	
DATE _ 0.1844. 19 2084	
FULL NAME OF FOURTH JOINT INV	ENTOR: Robert Reid
COUNTRY OF CITIZENSHIP:	United States
FULL RESIDENCE ADDRESS:	Oxford, Oxon, United Kingdom
FULL POST OFFICE ADDRESS:	The Forum 86 Milton Park Abingdon, Oxon OX14 4RY United Kingdom
SIGNATURE OF INVENTOR	Rikburnel
DATE	<u> </u>

FULL NAME OF FIFTH JOINT INVENTOR:

Michael Derek Waterfield

COUNTRY OF CITIZENSHIP:

United Kingdom

FULL RESIDENCE ADDRESS:

London, United Kingdom


FULL POST OFFICE ADDRESS:

Ludwig Institute for Cancer Research

91 Riding House Street London, W1P 8BT United Kingdom

SIGNATURE OF INVENTOR

DATE



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER FILING DATE GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS IND CLAIMS 09/936,408 01/08/2002 1645 1590 2543-1-020

CONFIRMATION NO. 3867

23565 **KLAUBER & JACKSON 411 HACKENSACK AVENUE** HACKENSACK, NJ 07601

COPY OF PAPERS ORIGINALLY FILED **FILING RECEIPT** *OC000000007358037*

Date Mailed: 01/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will TECH CENTER 1600/2900 generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Robert Amess, Cumnor, UNITED KINGDOM: Michael John O'Hare, London, UNITED KINGDOM: Rajesh Bhikhu Parekh, Nr. Wendlebury, UNITED KINGDOM: Robert Reid Street Oxford, UNITED KINGDOM: Michael Derek Waterfield, London, UNITED KINGDOM;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/GB00/00908 03/13/2000

Foreign Applications

UNITED KINGDOM 9905817.4 03/12/1999

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

. i 266

Title

Proteins for diagnosis and treatment of breast cancer

Preliminary Class

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).